Program
cevostamab
Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic, led by Hoffmann-La Roche.
Furthest: phase 3, since Apr 22, 20268 company-led studies, 7 open or runningNext primary completion: Nov 18, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 87 open or running | phase 3since Apr 22, 2026 | Sep 5, 2017 | Nov 18, 2026phase 1 · NCT05646836 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6160 cevostamab
, phase 3, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2017First study: phase 1 study in Multiple MyelomaFirst studyNCT03275103 · 355 enrolled · United States, Australia, Canada and more
- May 27, 2021Phase 1 study in Multiple MyelomaNCT04910568 · 186 planned · United States, Australia, Canada and more
- Aug 24, 2022Phase 2 study in Multiple MyelomaNCT05535244 · 90 enrolled · United States, Australia, Belgium and more
- Dec 2, 2022Phase 1 study in Multiple MyelomaNCT05646836 · 90 enrolled · Australia, Denmark, Greece and more
- Apr 9, 2025Phase 1 study in Multiple MyelomaNCT06934044 · 20 enrolled · China
- Apr 22, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07555938 · 380 planned · United States, Australia, Brazil and more
- Jun 1, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07629583 · 46 planned · Australia, Brazil, China and more
- Sep 14, 2026Phase 2 study in Multiple MyelomaNCT07825064 · 45 planned · Germany
Ahead
- Nov 18, 2026Primary completion: phase 1 study in Multiple MyelomaNCT05646836
- Feb 26, 2027Primary completion: phase 2 study in Multiple MyelomaNCT05535244
- Oct 31, 2028Primary completion: phase 3 study in Multiple MyelomaNCT07555938
- Nov 15, 2028Primary completion: phase 1 study in Multiple MyelomaNCT06934044
TargetBeta
“A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen foun…”NCIt, read by Claude
“A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found o”NCIt, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07825064Multiple Myeloma · Germany | 2 | Recruiting | Apr 13, 2029 | 45 |
| NCT07629583Lupus Erythematosus, Systemic · Australia, Brazil, China and more | 1 | Recruiting | Mar 29, 2030 | 46 |
| NCT07555938Multiple Myeloma · United States, Australia, Brazil and more | 3 | Recruiting | Oct 31, 2028 | 380 |
| NCT06934044Multiple Myeloma · China | 1 | Active, not recruiting | Nov 15, 2028 | 20 |
| NCT05646836Multiple Myeloma · Australia, Denmark, Greece and more | 1 | Active, not recruiting | Nov 18, 2026 | 90 |
| NCT05535244Multiple Myeloma · United States, Australia, Belgium and more | 2 | Active, not recruiting | Feb 26, 2027 | 90 |
| NCT04910568Multiple Myeloma · United States, Australia, Canada and more | 1 | Recruiting | Dec 21, 2028 | 186 |
| NCT03275103Multiple Myeloma · United States, Australia, Canada and more | 1 | Completed | Jan 7, 2026 | 355 |
How it is read
Names in the registry
- “Cevostamab”, 8 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 7 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.